This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Direct-acting antivirals have provided a highly viable cure for hepatitis C, but hepatitis B remains a complicated infectious disease and requires lengthy treatment and management in chronic cases. While HBV is vaccine-preventable, individuals who do contract HBV must be aware of its progression as it can lead to severe liver-related complications such as acute liver failure and may require liver transplantation.
The following reports provide recent findings on tenofovir treatment advocacy, premarket approval of an HBV assay, and the recent availability of the Heplisav-B vaccine in the U.S.:
- Combined tenofovir therapy reduces HBV antigens better than monotherapy
- Model predicts progression to acute liver failure in chronic HBV
- Heplisav-B HBV vaccine for adults available in US
- FDA grants premarket approval to HBV assay
- Patients with HBV who discontinue tenofovir relapse sooner
- Biologic non-TNF inhibitors increase HBV reactivation risk in rheumatic diseases
- Tenofovir alafenamide effectively treats HBV, no virologic resistance